Literature DB >> 19748218

Endovascular treatment of external iliac artery stenoses for claudication with systematic stenting.

Blandine Maurel1, Julien Lancelevee, David Jacobi, François Bleuet, Robert Martinez, Patrick Lermusiaux.   

Abstract

The results of the endovascular treatment of external iliac artery lesions in patients with claudication are not well known. In the literature, very often, the studied populations are not homogenous (people with claudication and with acute ischemia) and the external iliac artery is not differentiated from the primary iliac artery. Moreover, systematic stenting is still debated. Our goal was to study the results of systematic stenting for atheromatous lesions of the external iliac artery in a consecutive and homogenous population of patients with claudication. From June 2000 to December 2006, 90 external iliac arteries were treated with systematic stenting for atheromatous lesions in 81 consecutive patients with claudication (74 men and 7 women, aged 62+/-12 years). Lesions were classified according to the Trans-Atlantic Intersociety Consensus (TASC). Endovascular treatment was systematically chosen for TASC A (n=40) and B (n=30) patients and patients at high surgical risk for TASC C (n=18) and D (n=2). One hundred and seven stents were placed; they were 37+/-21 mm long with a 7+/-0.6mm diameter. Clinical examination and duplex follow-up were carried out at a minimum of 3 months and at the end of the follow-up. There was a 2.2% complication rate, without any deaths (retroperitoneal hematoma). Mean follow-up was 23 months (with a 13-month median). Primary patency rate was 97% (standard error [SE] 2%) at 1 year, 90% (SE 4.6%) at 2 years, and 84% (SE 6.6%) at 3 years. Secondary patency rate was 98% (SE 1.5%) at 1 year, 93% (SE 3.9%) at 2 years, and 93% (SE 4.5%) at 3 years. Ten restenoses were detected and treated by endovascular techniques (n=6), bypass (n=2), or medication (n=2). At the end of the follow-up, the patients were asymptomatic (n=62) or presented with a moderate (n=17) or severe (n=8) claudication. A patient with hemodialysis was amputated at the metatarsal level. No significant predictive restenosis factor was discovered. However, the C or D TASC classification seemed to favor an earlier restenosis (p=0.06). In conclusion, our study demonstrates that, in a larger population than in the literature, systematic stenting on the external iliac artery gives satisfying results in patients with claudication.

Entities:  

Mesh:

Year:  2009        PMID: 19748218     DOI: 10.1016/j.avsg.2008.05.019

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  4 in total

1.  Neointimal hyperplasia after stent placement across size-discrepant vessels in an animal study.

Authors:  Hisayuki Cho; Mineyoshi Nango; Yukimasa Sakai; Etsuji Sohgawa; Ken Kageyama; Shinichi Hamamoto; Toshiaki Kitayama; Akira Yamamoto; Yukio Miki
Journal:  Jpn J Radiol       Date:  2014-04-09       Impact factor: 2.374

2.  Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study.

Authors:  Timothy P Murphy; Donald E Cutlip; Judith G Regensteiner; Emile R Mohler; David J Cohen; Matthew R Reynolds; Joseph M Massaro; Beth A Lewis; Joselyn Cerezo; Niki C Oldenburg; Claudia C Thum; Michael R Jaff; Anthony J Comerota; Michael W Steffes; Ingrid H Abrahamsen; Suzanne Goldberg; Alan T Hirsch
Journal:  J Am Coll Cardiol       Date:  2015-03-17       Impact factor: 24.094

Review 3.  Self-expanding stents and aortoiliac occlusive disease: a review of the literature.

Authors:  Joost A Bekken; Hidde Jongsma; Jean-Paul Pm de Vries; Bram Fioole
Journal:  Med Devices (Auckl)       Date:  2014-05-02

4.  Comparison of results of endovascular stenting and bypass grafting for TransAtlantic Inter-Society (TASC II) type B, C and D iliac occlusive disease.

Authors:  Rimantas Benetis; Zana Kavaliauskiene; Aleksandras Antusevas; Rytis Stasys Kaupas; Donatas Inciura; Sarunas Kinduris
Journal:  Arch Med Sci       Date:  2016-04-12       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.